Skip to Main Content

Paper Details

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Front Oncol
0
2023
HCC, HCC-1937, HER2, HER2- receptor, HR, HR+, HR-, breast cancer, breast cancer cell line, breast cancers, breast tumors, cancer, cell line, drug, drug-resistant, early stage breast cancer, estrogen, estrogen receptor, fulvestrant, genes, hormone receptor positive subtypes, paclitaxel, paclitaxel resistant breast cancer cell lines, paclitaxel-resistant triple negative breast cancer cell line, patient, patients, triple, triple negative, triple negative breast cancer, triple negative breast cancer cell line, tumors
Author NameAffiliation
Amrita BasuUniversity of California san francisco
Amrita BasuUniversity of California san francisco
Christina YauUniversity of California san francisco
Christina YauUniversity of California san francisco
Denise M WolfUniversity of California san francisco
Sourav BandyopadhyayUniversity of California san francisco
James E KorkolaOregon Health and Science University
Laura J Van't VeerUniversity of California san francisco
  • 1 - 8

Datasets

Release 1.2